HEALTH● LOWAug 5 · Aug 5, 2026, 4:31 PM
United Therapeutics anticipates potential 2027 approvals for ralinepag and Tyvaso IPF while holding 2026 revenue outlook unchanged
Seeking Alpha Tech
United Therapeutics expects potential 2027 approvals for ralinepag and Tyvaso IPF while maintaining its 2026 revenue outlook. This provides an update on the company's product pipeline and financial projections.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH27m agoToluwanisings was rushed to 8 hospitals before death – PAVanguard NigeriaHEALTH1h agoPope Leo resumes work from the hospital as he awaits cancer treatment updateThe Independent WorldHEALTH1h agoKenya records second Ebola case as outbreak in Congo keeps growingEuroNews [en]HEALTH1h agoI work in the NHS and Malawi – we need to urgently rethink how we see health spendingThe Independent World